Cellebrite DI appoints new CEO, cuts full-year ARR outlook

Cellebrite DI (NASDAQ: CLBT ) reported second-quarter financial results on Thursday.

The transcript from the company's second-quarter earnings call has been provided below.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

View the webcast at Summary Cellebrite DI appointed Shiv Ramji as the new CEO, succeeding Tom Hogan, with a focus on accelerating platform growth and AI integration.

Q2 2026 results fell short of expectations, with ARR increasing by 21% to $508 million.

Revenue was $131 million, up 16% year-over-year, but missed guidance.

The company faced delays in closing large deals, particularly with U.S. federal and European government customers, due to new administrative and procurement requirements.

Cellebrite DI lowered its full-year ARR guidance to $550-$560 million but raised its adjusted EBITDA target, reflecting disciplined cost management.

Strategic initiatives include expanding the Genesis product and enhancing AI capabilities, with a focus on long-term growth and profitability.

Cellebrite DI's federal business and AI-driven products like Guardian Investigate and drone forensics showed promising early adoption.

Management emphasized the need for better sales execution and forecasting, acknowledging challenges in converting Insights customers to higher pricing tiers.

Full Transcript OPERATOR Welcome to the Cellebrite DI second quarter 2026 financial results conference call.

At this time, all participants have been placed on listen-only mode, and the floor will be open for your questions following the presentation.

If you would like to ask a question at that time, please press star 1 on your telephone keypad.

If at any point your question has been answered, you may remove yourself from the queue by pressing 2 so others can hear your questions clearly.

We ask that you pick up your handset for best sound quality.

Lastly, if you should require operator assistance, please press star 0.

I would now like to turn the call over to your first speaker today, Mr.

Andrew Kramer.

Mr.

Kramer, the floor is yours.

Andrew Kramer, Investor Relations Thank you very much, operator, and good morning, everybody.

Welcome to Cellebrite DI's second quarter 2026 financial results call.

I'm joined this morning by our primary speakers: Adam Klammer, Cellebrite DI's Chairman of the Board; Shiv Ramji, Cellebrite DI's new CEO; and David Barter, Cellebrite DI's CFO.

Shiv, Dave, and Marcus Jewell, our CRO, will participate on our Q&A session.

This call is being recorded, and a replay of the recording will be made available on our website shortly after the call along with a copy of the transcript.

Please note that today's press release and financial statements, including GAAP to non—GAAP reconciliations, are available on the investor relations website at investors.cellebrite.com.

In addition to the press release, we posted a separate investor presentation that provides an overview of the business and our recent financial performance.

I'd like to remind everybody who's listening on the webcast that the slide in your webcast viewer is a placeholder only.

There are no actual slides to accompany the prepared remarks.

We also published our historical financial information and supplemental data for the first two quarters of 2026, each quarter of 2025, along with the full year 2024 and 2023, on our investor relations website.

Additionally, unless stated otherwise, our discussion of our second quarter 2026 financial metrics, as well as the financial outlook, will be done on a non—GAAP basis only, and all historical comparisons are with the comparable periods of 2025.

I'd like to remind you that today's discussion will contain forward—looking statements, including, but not limited to, the company's business operations and financial performance.

All forward—looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward—looking statements not to occur.

Actual results could also differ materially from historical results and from forecasts.